Combination therapy with probiotics and anti-PD-L1 antibody synergistically ameliorates sepsis in mouse model
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Combining probiotics with anti-PD-L1 therapy significantly improves survival in septic mice. This approach reduces inflammation, enhances immune cell balance, and inhibits key signaling pathways for better protection.
Area Of Science
- Immunology
- Microbiology
- Pharmacology
Background
- Sepsis is a life-threatening condition characterized by dysregulated immune responses and organ dysfunction.
- Current treatments for sepsis have limitations, highlighting the need for novel therapeutic strategies.
- Probiotics and immune checkpoint inhibitors like anti-PD-L1 antibodies show potential in modulating immune responses.
Purpose Of The Study
- To investigate the combined protective effects of probiotics and anti-PD-L1 antibody in a mouse model of sepsis.
- To elucidate the underlying mechanisms, including immune cell balance, inflammatory markers, and signaling pathways.
Main Methods
- Sepsis was induced in mice using cecal ligation and puncture (CLP) followed by lipopolysaccharide (LPS) injection.
- Mice were treated with vehicle, probiotics, anti-PD-L1 antibody, or a combination therapy.
- Immune parameters, cytokine levels, oxidative stress, lung pathology, neutrophil apoptosis, and PI3K/Akt pathway activation were assessed.
Main Results
- Combined probiotic and anti-PD-L1 therapy significantly increased the 7-day survival rate in septic mice.
- The combination treatment reduced pro-inflammatory cytokines (IL-6, IL-8, IL-17), increased anti-inflammatory cytokines (IL-10, IFN-γ), and improved Th17/Treg balance.
- Enhanced protection was associated with increased polymorphonuclear neutrophil apoptosis and inhibition of PI3K/Akt pathway phosphorylation.
Conclusions
- Combination therapy with probiotics and anti-PD-L1 antibody offers superior protective effects against sepsis compared to monotherapy.
- The therapeutic benefits are mediated by reduced systemic inflammation, modulated immune cell apoptosis, and regulation of the PI3K/Akt signaling pathway.
- This synergistic approach presents a promising strategy for managing sepsis by enhancing immune homeostasis.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.